SOURCE Particle Sciences
BETHLEHEM, Pa., Sept. 2, 2014 /PRNewswire/ -- Particle Sciences, the leading CDMO for drug eluting devices, again adds to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. According to Karl Mueller, Particle Sciences' Associate Director Clinical Production, "The company has been expanding at a nice pace adding clean room square footage, equipment and staff across the board, all aimed at better serving our clients. The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites. The device group has been extremely productive bringing several products into the clinic in the last few months with more in pipeline. Particle Sciences is unique in its ability to bring such products from concept to the clinic, especially when they involve highly potent compounds which most implants do." Mark Mitchnick, Particle Sciences' CEO added, "The staff continues to skillfully execute on the goal of being the premiere CDMO in the area of complex formulations which of course includes drug eluting devices. In response, the marketplace is validating the effort and our business is growing at a record pace."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email firstname.lastname@example.org, or contact us at (610) 861- 4701 for information.
©2012 PR Newswire. All Rights Reserved.